{"entity":{"id":"idea-bio2-matrix-stiffness-prevention","kind":"idea","name":"Soften the tissue that new metastases need in order to grow","aka":[],"tldr":"Cancer cells need stiff, cross-linked tissue scaffolding to settle and grow in a new organ. Blocking the enzymes that build it may stop new colonies taking hold.","summary":"LOX and LOXL2 cross-link collagen to create the stiff matrix required for metastatic outgrowth, and hypoxia-driven LOX secretion prepares bone and lung niches. An anti-LOXL2 antibody failed in fibrosis and in advanced pancreatic cancer, but was never tested in the prevention setting where the biology predicts benefit and the target burden is small.","asOf":"2026-09-08","links":[{"label":"Bottleneck evidence (Metastasis is understood least and studied last): Dillekås et al., Are 90% of deaths from cancer caused by metastases? (Cancer Medicine 2019)","url":"https://doi.org/10.1002/cam4.2474"}],"tags":[],"related":[],"cancers":["pancreatic","breast-hr-positive"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":["hif-vhl","emt"],"terms":["desmoplasia"],"trials":[],"people":["erik-sahai"],"bottlenecks":["b-metastasis-biology","b-negative-results"],"keyPapers":["paper-dillekas-cancer-med"],"journals":[],"dependsOn":[],"notes":[],"hypothesis":"LOX or LOXL2 inhibition given adjuvantly, when only micrometastatic disease is present, delays radiographic metastasis, while having no effect on established macroscopic disease.","rationale":"Matrix cross-linking is rate-limiting for outgrowth, not for the survival of an already vascularised lesion, which would explain why treatment trials failed. Early-intervention-only benefit has precedent in anti-fibrotic therapy for lung fibrosis.","test":"Test the setting-dependence in mice first: the identical agent in adjuvant versus established-metastasis designs. Only a large adjuvant-specific effect should trigger a human trial in high-risk resected disease.","maturity":"preclinical-evidence","actor":"research","cost":"medium","horizonYears":8},"route":"/ideas/idea-bio2-matrix-stiffness-prevention/","neighbours":{"cancer":[{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"pancreatic","kind":"cancer","name":"Pancreatic ductal adenocarcinoma","route":"/cancers/pancreatic/"}],"pathway":[{"id":"emt","kind":"pathway","name":"Epithelial-mesenchymal transition & drug efflux","route":"/pathways/emt/"},{"id":"hif-vhl","kind":"pathway","name":"VHL / HIF oxygen sensing","route":"/pathways/hif-vhl/"}],"term":[{"id":"desmoplasia","kind":"term","name":"Desmoplasia (tumour stroma)","route":"/terms/desmoplasia/"}],"person":[{"id":"erik-sahai","kind":"person","name":"Erik Sahai","route":"/people/erik-sahai/"}],"bottleneck":[{"id":"b-negative-results","kind":"bottleneck","name":"Failures are hidden","route":"/bottlenecks/b-negative-results/"},{"id":"b-metastasis-biology","kind":"bottleneck","name":"Metastasis is understood least and studied last","route":"/bottlenecks/b-metastasis-biology/"}],"paper":[{"id":"paper-dillekas-cancer-med","kind":"paper","name":"Are 90% of deaths from cancer caused by metastases?","route":"/key-papers/paper-dillekas-cancer-med/"}]}}